Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics, Polymedco to Team up on North American Launch of Colorectal Cancer Test

NEW YORK (GenomeWeb News) – Epigenomics said today it has reached a deal with Polymedco to jointly commercialize Epigenomics' Epi proColon colorectal cancer screen in North America.

The test is currently under review by the US Food and Drug Administration, and Germany-based Epigenomics has said that approval is anticipated later this year. Upon approval, Polymedco would deploy its dedicated colorectal cancer sales force, technical support staff, administration, logistics, and other support functions to launch and market the test, Epigenomics said.

Both firms will jointly work on marketing, launch, and development strategies, and collaborate on reimbursement efforts for Epi proColon. Epigenomics will continue to be responsible for manufacturing the test, and for supporting it "from the medical and regulatory point of view, including the activities necessary to achieve inclusion in major cancer screening guidelines" after FDA approval, it said.

As part of the deal, Epigenomics and Polymedco have agreed to a combined transfer price and to share profits, subject to minimum annual sales of test kits to Polymedco.

Based in Cortlandt Manor, NY, Polymedco is the largest provider of colorectal cancer screening tests in North America, according to Epigenomics, and has more than $50 million in annual sales of cancer diagnostic products. Its customer base includes more than 1,500 laboratories.

"Polymedco's commitment to the [colorectal cancer] screening space will accelerate our commercial rollout in North America and will mean a significant time and resource advantage for Epigenomics in the launch of Epi proColon," Noel Doheny, CEO of Epigenomics' US subsidiary, said in a statement.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.